Information: Detta är inte den senaste versionen av datamodellen. Du hittar en versionsöversikt till vänster under versioner. Den senaste versionen hittar du här.
Information:
Fel:
ID
29823
Beskrivning
Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01008358
Länk
https://clinicaltrials.gov/show/NCT01008358
Nyckelord
Versioner (4)
- 2018-04-21 2018-04-21 -
- 2018-04-21 2018-04-21 -
- 2018-04-22 2018-04-22 -
- 2021-09-20 2021-09-20 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
22 april 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Hepatocellular Carcinoma NCT01008358
Eligibility Hepatocellular Carcinoma NCT01008358
- StudyEvent: Eligibility
Similar models
Eligibility Hepatocellular Carcinoma NCT01008358
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Liver carcinoma
Item
unequivocal diagnosis of hcc
boolean
C2239176 (UMLS CUI [1])
Disease unresectable | Disease Inappropriate Therapeutic procedure Locoregional
Item
unresectable disease not amenable to locoregional treatment.
boolean
C0012634 (UMLS CUI [1,1])
C1519810 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C1548788 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C1947913 (UMLS CUI [2,4])
C1519810 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C1548788 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C1947913 (UMLS CUI [2,4])
Washout Period Post Sorafenib | Washout Period Post Pharmaceutical Preparations Systemic
Item
a 4-week washout period after sorafenib or any other systemic agent
boolean
C1710661 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C1516119 (UMLS CUI [1,3])
C1710661 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0013227 (UMLS CUI [2,3])
C0205373 (UMLS CUI [2,4])
C0687676 (UMLS CUI [1,2])
C1516119 (UMLS CUI [1,3])
C1710661 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0013227 (UMLS CUI [2,3])
C0205373 (UMLS CUI [2,4])
Washout Period Post Brachytherapy | Washout Period Post External Radiation
Item
a 2-month washout period after internal or external radiation
boolean
C1710661 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C0006098 (UMLS CUI [1,3])
C1710661 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C1517033 (UMLS CUI [2,3])
C0687676 (UMLS CUI [1,2])
C0006098 (UMLS CUI [1,3])
C1710661 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C1517033 (UMLS CUI [2,3])
Hepatitis C, Chronic
Item
hcv chronic infection
boolean
C0524910 (UMLS CUI [1])
Child-Pugh Classification
Item
child-pugh stage a or b
boolean
C2347612 (UMLS CUI [1])
Measurable Disease
Item
measurable disease according to recist criteria
boolean
C1513041 (UMLS CUI [1])
ECOG performance status
Item
ecog < 2
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
expected survival > 3 months
boolean
C0023671 (UMLS CUI [1])
Liver function | Renal function | Hematologic function
Item
adequate liver, renal and blood functions
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0221130 (UMLS CUI [3])
C0232804 (UMLS CUI [2])
C0221130 (UMLS CUI [3])
Informed Consent
Item
ability to sign informed consent
boolean
C0021430 (UMLS CUI [1])
CTL4 inhibitors
Item
previous treatment with an anti-ctl-4 agent
boolean
C3711064 (UMLS CUI [1,1])
C0243077 (UMLS CUI [1,2])
C0243077 (UMLS CUI [1,2])
Communicable Disease Serious compromises General health | Disease Serious compromises General health
Item
serious infections or disease compromising general health status
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C2945640 (UMLS CUI [1,3])
C0424575 (UMLS CUI [1,4])
C0012634 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C2945640 (UMLS CUI [2,3])
C0424575 (UMLS CUI [2,4])
C0205404 (UMLS CUI [1,2])
C2945640 (UMLS CUI [1,3])
C0424575 (UMLS CUI [1,4])
C0012634 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C2945640 (UMLS CUI [2,3])
C0424575 (UMLS CUI [2,4])
Autoimmune Disease Treatment required for
Item
autoimmune disease that requires therapy
boolean
C0004364 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
C0332121 (UMLS CUI [1,2])
Immunosuppressive Agents
Item
treatment with immunosuppressors
boolean
C0021081 (UMLS CUI [1])
Investigational New Drugs
Item
treatment with investigational agents
boolean
C0013230 (UMLS CUI [1])
Cancer Other | Exception Skin carcinoma | Exception Bladder Neoplasm Superficial
Item
other neoplasms except skin and bladder superficial tumors
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0005695 (UMLS CUI [3,2])
C0205124 (UMLS CUI [3,3])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0005695 (UMLS CUI [3,2])
C0205124 (UMLS CUI [3,3])
Pregnancy | Breast Feeding
Item
pregnancy or lactation
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
CNS metastases
Item
snc metastasis
boolean
C0686377 (UMLS CUI [1])
HIV Infection
Item
hiv infection
boolean
C0019693 (UMLS CUI [1])
Heart Disease New York Heart Association Classification
Item
relevant heart disease (nyha class iii or iv)
boolean
C0018799 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C1275491 (UMLS CUI [1,2])